Cargando...
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, inc...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3253822/ https://ncbi.nlm.nih.gov/pubmed/21484496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-011-0172-y |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|